8-K filing — Theriva Biologics, Inc. (TOVX)
Filed: 2026-08-11 AccNo: 0001104659-26-093782 Size: 310 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
8-K filing — Theriva Biologics, Inc. (TOVX)
Filed: 2026-08-04 AccNo: 0001104659-26-090064 Size: 235 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.07: Submission of Matters to a Vote of Security Holders Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 4, 2026, 11:20 AM
- Checked
- Aug 4, 2026, 11:20 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Theriva Biologics Q2 EPS $(0.07) Misses $(0.05) Estimate
Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 96.37 percent increase over losses of $(1.93) per share from
Read original at benzingaTheriva Biologics Doses First Patient In VIRAGE2 Phase 2a Clinical Trial, Small Proof-Of-Concept Study Evaluating More Frequent Repeated Dosing Of VCN-01 In First-Line Metastatic PDAC Patients Treated With Gemcitabine/Nab-Paclitaxel Chemotherapy
Read original at benzingaTheriva Biologics Receives Spanish Agency Of Medicines And Medical Devices Authorization To Initiate Its VIRAGE2 Clinical Trial
Read original at benzinga